Cart
sales@molnova.com
NVP-BKM120
CAS No. 944396-07-0
NVP-BKM120 ( BKM-120;Buparlisib )
Catalog No. M16766 CAS No. 944396-07-0
NVP-BKM120 (BKM-120, Buparlisib)is a potent, selective, orally bioavailable inhibitor of class I PI3K isoforms.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 51 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 86 | In Stock |
|
| 50MG | 105 | In Stock |
|
| 100MG | 132 | In Stock |
|
| 200MG | 222 | In Stock |
|
| 500MG | 402 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNVP-BKM120
-
NoteResearch use only, not for human use.
-
Brief DescriptionNVP-BKM120 (BKM-120, Buparlisib)is a potent, selective, orally bioavailable inhibitor of class I PI3K isoforms.
-
DescriptionNVP-BKM120 (BKM-120, Buparlisib)is a potent, selective, orally bioavailable inhibitor of class I PI3K isoforms with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/β/δ/γ, respectively; much less effectively inhibits the class III PI3K Vps34 and mTOR, and has no effect on PI4Kβ and several other kinases; prevents the growth of assorted cancer cell lines when used at 5 μM and inhibits tumor growth in vivo.Blood Cancer Phase 2 Clinical
-
SynonymsBKM-120;Buparlisib
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
Recptorp110α;p110β;p110γ;p110δ;Vps34
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number944396-07-0
-
Formula Weight410.39
-
Molecular FormulaC18H21F3N6O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESNC1=NC=C(C2=CC(=NC(=N2)N2CCOCC2)N2CCOCC2)C(=C1)C(F)(F)F
-
Chemical Name2-Pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Maira SM, et al. Mol Cancer Ther. 2012 Feb;11(2):317-28.
2. Pei Y, et al. Cancer Cell. 2012 Feb 14;21(2):155-67.
3. Koul D, et al. Clin Cancer Res. 2012 Jan 1;18(1):184-95.
2. Pei Y, et al. Cancer Cell. 2012 Feb 14;21(2):155-67.
3. Koul D, et al. Clin Cancer Res. 2012 Jan 1;18(1):184-95.
molnova catalog
related products
-
AZD 6482
A potent, selective and ATP competitive PI3Kβ inhibitor with IC50 of 10 nM.
-
Loureirin A
Loureirin A has an inhibitory effect on platelet activation perhaps through an impairment of PI3K/Akt signaling.Loureirin A negatively affects agonist-induced platelet aggregation such as collagen collagen-related peptide (CRP) ADP and thrombin.
-
AZD8835
AZD8835 (AZD-8835) is a potent, selective inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 and 5.7 nM.
